B-CLL patient information
| Clinical characteristics . | % Cell death above control* . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID . | Age/sex . | Binet stage . | Previous therapy . | TP53 (Del17p) analysis . | WBC, ×109/L . | CD20+ cells, % . | CD20 expression, MFI† . | GA101 . | GA101 (NG)‡ . | Rituximab . | Ofatumumab . |
| CLL31 | 64/M | Relapsed B | Chlorambucil, fludarabine, cyclophosphamide | Negative | 288.5 | 96.8 | 151 | 20 | 22.1 | −2.3 | 3.4 |
| CLL35 | 79/F | A | No prior therapy | Negative | 46.7 | 88.5 | 160 | 14 | 15 | 1.6 | 5.6 |
| CLL39 | 63/M | B | No prior therapy | Negative | 20 | 86.8 | 122 | 20.7 | 17.7 | 5.5 | 2 |
| CLL42 | 74/F | Relapsed C | Chlorambucil and steroids | Negative | 66.2 | 96.1 | 134 | 27.7 | 28.6 | 3.9 | 4.7 |
| Clinical characteristics . | % Cell death above control* . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID . | Age/sex . | Binet stage . | Previous therapy . | TP53 (Del17p) analysis . | WBC, ×109/L . | CD20+ cells, % . | CD20 expression, MFI† . | GA101 . | GA101 (NG)‡ . | Rituximab . | Ofatumumab . |
| CLL31 | 64/M | Relapsed B | Chlorambucil, fludarabine, cyclophosphamide | Negative | 288.5 | 96.8 | 151 | 20 | 22.1 | −2.3 | 3.4 |
| CLL35 | 79/F | A | No prior therapy | Negative | 46.7 | 88.5 | 160 | 14 | 15 | 1.6 | 5.6 |
| CLL39 | 63/M | B | No prior therapy | Negative | 20 | 86.8 | 122 | 20.7 | 17.7 | 5.5 | 2 |
| CLL42 | 74/F | Relapsed C | Chlorambucil and steroids | Negative | 66.2 | 96.1 | 134 | 27.7 | 28.6 | 3.9 | 4.7 |
WBC indicates white blood cells; MFI, median fluorescence intensity; M, male; and F, female.
Direct programmed cell death induced by anti-CD20 mAbs (as depicted in Figure 3A).
MFI above isotype control detected by treatment of cells with rituximab (5 μg/mL) followed by PE-conjugated anti-human Fc (1:100) and analyzed by flow cytometry.
GA101 (NG) is a variant of GA101 with a wild-type, non-glycoengineered human IgG1 Fc domain.